Gene therapy for epidermolysis bullosa

Dr. Peter Marinkovic, an associate professor at Stanford, discusses exciting advancements in gene therapy for Epidermolysis Bullosa (EB), particularly focusing on dystrophic EB, a severe blistering skin condition. Despite traditional supportive care, current treatments fail to stop blistering, motivating researchers to explore gene therapies that aim to deliver functional collagen 7, which is deficient in patients with EB. One promising approach utilizes a modified HSV-1 virus to transport the collagen 7 gene directly into patient cells. Early phase trials have shown that applying this gene therapy gel to wounds can lead to significant healing, evidenced by improved wound closure and fewer adverse events compared to placebo treatments. The therapy demonstrated not only efficacy in healing wounds but also safety over repeated applications, which may revolutionize treatment protocols for EB. Furthermore, a case study highlights a patient who regained vision after using this therapy in the eye, indicating potential beyond skin applications. Ongoing research aims to explore this therapy's effectiveness in other areas affected by EB, emphasizing a positive future for gene-based treatments in dermatology.